| Original language | English (US) |
|---|---|
| Pages (from-to) | 642-644 |
| Number of pages | 3 |
| Journal | Headache |
| Volume | 62 |
| Issue number | 5 |
| DOIs |
|
| State | Published - May 2022 |
Keywords
- headache
- medication overuse
- migraine
- pragmatic clinical trial
ASJC Scopus subject areas
- Neurology
- Clinical Neurology
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Headache, Vol. 62, No. 5, 05.2022, p. 642-644.
Research output: Contribution to journal › Comment/debate › peer-review
}
TY - JOUR
T1 - Treatment of chronic migraine with medication overuse
T2 - A perspective
AU - Schwedt, Todd J.
AU - Robert, Teri
AU - Dodick, David W.
N1 - Funding Information: Todd Schwedt: within the prior 24 months, Schwedt has received consulting fees from Abbvie, Biodelivery Science, Biohaven, Click Therapeutics, Eli Lilly, Equinox, Ipsen, Lundbeck, Novartis, Precision HEOR, Satsuma, and Tonix Pharma. He has stock options in Aural Analytics and Nocira. He has received royalties from Up To Date. He has received research grant funding from Amgen, Henry Jackson Foundation, Mayo Clinic, National Institutes of Health, Patient Centered Outcomes Research Institute, SPARK Neuro, and the United States Department of Defense. Teri Robert: no conflicts of interest to declare. David W. Dodick reports the following conflicts: consulting: Amgen, CapiThera, Cerecin, Ceruvia Lifesciences, Cooltech, Ctrl M, Allergan, Abbvie, Biohaven, GSK, Lundbeck, Eli Lilly, Novartis, Impel, Satsuma, Theranica, WL Gore, Genentech, Nocira, Perfood, Praxis, Pfizer, AYYA Biosciences, Revance; honoraria/expense reimbursement/royalties: American Academy of Neurology, Headache Cooperative of the Pacific, MF Med Ed Research, Biopharm Communications, CEA Group Holding Company (Clinical Education Alliance LLC), Teva (speaking), Amgen (speaking), Eli Lilly (speaking), Lundbeck (speaking), Vector Psychometric Group, Clinical Care Solutions, CME Outfitters, Curry Rockefeller Group, DeepBench, Global Access Meetings, KLJ Associates, Academy for Continued Healthcare Learning, Majallin LLC, Medlogix Communications, Medica Communications LLC, MJH Lifesciences, Miller Medical Communications, Synapse, WebMD Health/Medscape, Wolters Kluwer, Oxford University Press, Cambridge University Press; non‐profit board membership: American Brain Foundation, American Migraine Foundation, ONE Neurology, Precon Health Foundation, International Headache Society Global Patient Advocacy Coalition, Atria Health Collaborative, Domestic Violence HOPE Foundation/Panfila, CSF Leak Foundation; research support: Department of Defense, National Institutes of Health, Henry Jackson Foundation, Sperling Foundation, American Migraine Foundation, Patient Centered Outcomes Research Institute (PCORI); stock options/shareholder/patents/board of directors: Ctrl M (options), Aural analytics (options), ExSano (options), Palion (options), Healint (options), Theranica (options), Second Opinion/Mobile Health (options), Epien (options/board), Nocira (options), Matterhorn (shares/board), Ontologics (shares/board), King‐Devick Technologies (options/board), Precon Health (options/board), AYYA Biosciences (options), Axon Therapeutics (options/board), Cephalgia Group (options/board), Atria Health (options/salary); patent 17189376.1‐1466:vTitle: Botulinum Toxin Dosage Regimen for Chronic Migraine Prophylaxis (no fee/compensation/royalty).
PY - 2022/5
Y1 - 2022/5
KW - headache
KW - medication overuse
KW - migraine
KW - pragmatic clinical trial
UR - http://www.scopus.com/inward/record.url?scp=85129922422&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85129922422&partnerID=8YFLogxK
U2 - 10.1111/head.14314
DO - 10.1111/head.14314
M3 - Comment/debate
C2 - 35524461
AN - SCOPUS:85129922422
SN - 0017-8748
VL - 62
SP - 642
EP - 644
JO - Headache
JF - Headache
IS - 5
ER -